

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number
WO 2005/065658 A1

(51) International Patent Classification⁷: **A61K 9/16**

(21) International Application Number:
PCT/KR2005/000066

(22) International Filing Date: 10 January 2005 (10.01.2005)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2004-0001597 9 January 2004 (09.01.2004) KR
10-2004-0067569 26 August 2004 (26.08.2004) KR

(71) Applicant (for all designated States except US): HANMI PHARM. CO., LTD. [KR/KR]; #893-5, Hajeon-ri, Paltanmyeon, Hwasong-gun, Kyungki-do 445-910 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WOO, Jong Soo [KR/KR]; Daewolmaeul 821-105, #914, Jeongja-dong, Jangsan-gu, Suwon-si, Kyungki-do 440-300 (KR). CHANG, Hee Chul [KR/KR]; 302-ho, #290-4, Gosaik-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-360

(KR). YI, Hong Gi [KR/KR]; Samick 2-cha Apt. 202-604, Homaesil-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-708 (KR).


(74) Agents: JANG, Seongku et al.; 19th Fl., KEC Building, #275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CEFUROXIME AXETIL GRANULE AND PROCESS FOR THE PREPARATION THEREOF



(57) Abstract: A cefuroxime axetil granule composition comprising a non-crystalline cefuroxime axetil solid dispersion or a substantially amorphous cefuroxime axetil, sucrose fatty acid ester, methacrylic acid-ethylacrylate copolymer and a disintegrating agent has highly desirable performance characteristics in terms of masking the bitterness of cefuroxime axetil, as well as high bioavailability and stability of cefuroxime axetil, and thus, can be advantageously used for oral administration of cefuroxime axetil.

WO 2005/065658 A1



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.